Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SC12267: Phase IIa data

In a double-blind, European Phase IIa trial in 121 patients, SC12267 missed the primary

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE